These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 30292480)
1. Antimicrobial resistance following mass azithromycin distribution for trachoma: a systematic review. O'Brien KS; Emerson P; Hooper PJ; Reingold AL; Dennis EG; Keenan JD; Lietman TM; Oldenburg CE Lancet Infect Dis; 2019 Jan; 19(1):e14-e25. PubMed ID: 30292480 [TBL] [Abstract][Full Text] [Related]
2. Mass distribution of azithromycin for trachoma control is associated with increased risk of azithromycin-resistant Streptococcus pneumoniae carriage in young children 6 months after treatment. Coles CL; Mabula K; Seidman JC; Levens J; Mkocha H; Munoz B; Mfinanga SG; West S Clin Infect Dis; 2013 Jun; 56(11):1519-26. PubMed ID: 23487375 [TBL] [Abstract][Full Text] [Related]
3. Adverse and beneficial secondary effects of mass treatment with azithromycin to eliminate blindness due to trachoma in Nepal. Fry AM; Jha HC; Lietman TM; Chaudhary JS; Bhatta RC; Elliott J; Hyde T; Schuchat A; Gaynor B; Dowell SF Clin Infect Dis; 2002 Aug; 35(4):395-402. PubMed ID: 12145722 [TBL] [Abstract][Full Text] [Related]
4. Impact of azithromycin administration for trachoma control on the carriage of antibiotic-resistant Streptococcus pneumoniae. Batt SL; Charalambous BM; Solomon AW; Knirsch C; Massae PA; Safari S; Sam NE; Everett D; Mabey DC; Gillespie SH Antimicrob Agents Chemother; 2003 Sep; 47(9):2765-9. PubMed ID: 12936971 [TBL] [Abstract][Full Text] [Related]
5. Stopping azithromycin mass drug administration for trachoma: A systematic review. Mahmud H; Landskroner E; Amza A; Aragie S; Godwin WW; de Hostos Barth A; O'Brien KS; Lietman TM; Oldenburg CE PLoS Negl Trop Dis; 2021 Jul; 15(7):e0009491. PubMed ID: 34237074 [TBL] [Abstract][Full Text] [Related]
7. Short-term increase in prevalence of nasopharyngeal carriage of macrolide-resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. Bojang E; Jafali J; Perreten V; Hart J; Harding-Esch EM; Sillah A; Mabey DC; Holland MJ; Bailey RL; Roca A; Burr SE BMC Microbiol; 2017 Mar; 17(1):75. PubMed ID: 28351345 [TBL] [Abstract][Full Text] [Related]
8. Community treatment with azithromycin for trachoma is not associated with antibiotic resistance in Streptococcus pneumoniae at 1 year. Gaynor BD; Holbrook KA; Whitcher JP; Holm SO; Jha HC; Chaudhary JS; Bhatta RC; Lietman T Br J Ophthalmol; 2003 Feb; 87(2):147-8. PubMed ID: 12543738 [TBL] [Abstract][Full Text] [Related]
9. Mass drug administration of azithromycin for trachoma reduces the prevalence of genital Chlamydia trachomatis infection in the Solomon Islands. Marks M; Bottomley C; Tome H; Pitakaka R; Butcher R; Sokana O; Kako H; Solomon AW; Mabey DC Sex Transm Infect; 2016 Jun; 92(4):261-5. PubMed ID: 26888658 [TBL] [Abstract][Full Text] [Related]
10. The decline of pneumococcal resistance after cessation of mass antibiotic distributions for trachoma. Haug S; Lakew T; Habtemariam G; Alemayehu W; Cevallos V; Zhou Z; House J; Ray K; Porco T; Rutar T; Keenan J; Lietman TM; Gaynor BD Clin Infect Dis; 2010 Sep; 51(5):571-4. PubMed ID: 20649409 [TBL] [Abstract][Full Text] [Related]
11. Is there evidence for resistance of ocular Chlamydia trachomatis to azithromycin after mass treatment for trachoma control? West SK; Moncada J; Munoz B; Mkocha H; Storey P; Hardick J; Gaydos CA; Quinn TC; Schachter J J Infect Dis; 2014 Jul; 210(1):65-71. PubMed ID: 24446528 [TBL] [Abstract][Full Text] [Related]
12. Impact of a single round of mass drug administration with azithromycin on active trachoma and ocular Chlamydia trachomatis prevalence and circulating strains in The Gambia and Senegal. Harding-Esch EM; Holland MJ; Schémann JF; Sillah A; Sarr B; Christerson L; Pickering H; Molina-Gonzalez S; Sarr I; Andreasen AA; Jeffries D; Grundy C; Mabey DCW; Herrmann B; Bailey RL Parasit Vectors; 2019 Oct; 12(1):497. PubMed ID: 31640755 [TBL] [Abstract][Full Text] [Related]
13. Azithromycin for the treatment and control of trachoma. Burton MJ; Frick KD; Bailey RL; Bowman RJ Expert Opin Pharmacother; 2002 Feb; 3(2):113-20. PubMed ID: 11829725 [TBL] [Abstract][Full Text] [Related]
14. Community-level Association between Clinical Trachoma and Ocular Chlamydia Infection after MASS Azithromycin Distribution in a Mesoendemic Region of Niger. Amza A; Kadri B; Nassirou B; Cotter SY; Stoller NE; West SK; Bailey RL; Porco TC; Keenan JD; Lietman TM; Oldenburg CE Ophthalmic Epidemiol; 2019 Aug; 26(4):231-237. PubMed ID: 30957594 [No Abstract] [Full Text] [Related]
15. Increased carriage of macrolide-resistant fecal E. coli following mass distribution of azithromycin for trachoma control. Seidman JC; Coles CL; Silbergeld EK; Levens J; Mkocha H; Johnson LB; Muñoz B; West SK Int J Epidemiol; 2014 Aug; 43(4):1105-13. PubMed ID: 24659584 [TBL] [Abstract][Full Text] [Related]
17. Trachoma and ocular Chlamydia trachomatis were not eliminated three years after two rounds of mass treatment in a trachoma hyperendemic village. West SK; Munoz B; Mkocha H; Gaydos C; Quinn T Invest Ophthalmol Vis Sci; 2007 Apr; 48(4):1492-7. PubMed ID: 17389476 [TBL] [Abstract][Full Text] [Related]
18. Safety of azithromycin in infants under six months of age in Niger: A community randomized trial. Oldenburg CE; Arzika AM; Maliki R; Kane MS; Lebas E; Ray KJ; Cook C; Cotter SY; Zhou Z; West SK; Bailey R; Porco TC; Keenan JD; Lietman TM; PLoS Negl Trop Dis; 2018 Nov; 12(11):e0006950. PubMed ID: 30419040 [TBL] [Abstract][Full Text] [Related]